Chemical Compound

2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir; GSK 1349572; S@fs:GSK1349572; Soltegravir; Tivicay; GSK 1349572B

CAS Registry Number 1051375-16-6
2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir; GSK 1349572; S@fs:GSK1349572; Soltegravir; Tivicay; GSK 1349572B 结构式
Primary record

2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir; GSK 1349572; S@fs:GSK1349572; Soltegravir; Tivicay; GSK 1349572B

库存
3,502 克
纯度
98.1 %
CAS
1051375-16-6

化合物标识与属性

CAS
1051375-16-6
PubChem CID
54726191
SMILES
C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
Canonical SMILES
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12

名称与同义词

  • Dolutegravir
  • Tivicay
  • 1051375-16-6
  • GSK1349572
  • dolutegravirum
  • Cabotegravir
  • Soltegravir
  • Dolutegravir?
  • Dolutegravir DTG
  • S/GSK1349572
  • Dolutegravir (GSK1349572)
  • Dolutegravir [USAN]
  • Tivicay (TN)
  • GSK 1349572
  • GSK-1349572
  • Dolutegravir (USAN)
  • Dolutegravir free acid
  • DKO1W9H7M1
  • 3s3m
  • 3s3n
  • 3s3o
  • Dolutegravir (Standard)
  • Dolutegravir [USAN:INN]
  • RefChem:56964
  • UNII-DKO1W9H7M1
  • DOLUTEGRAVIR [MI]
  • DOLUTEGRAVIR SODIUM
  • DOLUTEGRAVIR [INN]
  • cc-13
  • CHEBI:76010
  • D00YZD
  • D0W0TW
  • DOLUTEGRAVIR [VANDF]
  • Dolutegravir Sodium ( API)
  • S-349572
  • SCHEMBL82071
  • HSDB 8152
  • MLS006011137
  • DOLUTEGRAVIR [WHO-DD]
  • C20H19F2N3O5
  • DTXSID90909356
  • MFCD20488027
  • GTPL7365
  • orb1300988
  • QCR-34
  • CHEMBL1229211
  • SCHEMBL15397915
  • SCHEMBL29357473
  • GSK1349572A
  • J05AX12
  • RHWKPHLQXYSBKR-BMIGLBTASA-N
  • S-GSK1349572
  • DTXCID701338419
  • GLXC-90267
  • AOB87150
  • EX-A1695
  • 1051375-16-6 (free)
  • ABP000915
  • BDBM50062551
  • EBC-27030
  • HY-13238R
  • s2667
  • ZINC58581064
  • AKOS025396657
  • S/GSK-1349572
  • ACN-041355
  • BCP9000620
  • C20-H19-F2-N3-O5
  • CCG-268876
  • CS-0454
  • DB08930
  • FD43372
  • RL00238
  • (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide
  • Dolutegravir (0.1 mg/mL in Methanol)
  • NCGC00346629-01
  • NCGC00346629-02
  • NCGC00346629-06
  • NCGC00346629-11
  • AC-28371
  • AS-75277
  • BC638753
  • HY-13238
  • SC-85939
  • SMR004702915
  • (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
  • AB0033823
  • A4074
  • NS00099377
  • X7595
  • J3.008.741K
  • S/GSK1349572,GSK1349572
  • D10066
  • Q-4931
  • EN300-7409916
  • A854801
  • F799806
  • Q937224
  • (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide
  • (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
  • Z2235801952
  • 1062161-90-3, WYE687, WYE 687
  • B0084-438457
  • 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
  • DTG
  • (14C)-(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-(1,3)oxazino(3,2-a)pyrido(1,2-d)pyrazine-9-carboxamide
  • (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0(3),?]tetradeca-10,13-diene-13-carboxamide
  • (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0,3,8]tetradeca-10,13-diene-13-carboxamide
  • (4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE
  • (4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide
  • (4R,12aS)-N-((2,4-difluorophenyl)methyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido(5,6)pyrazino(2,6-b)(1,3)oxazine-9-carboxamide
  • (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-a]pyrido[1,2-d]pyrazine-9-carboxamide
  • (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide
  • (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
  • (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide
  • (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide
  • (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
  • (4R,9aS)-5-Hydroxy-3,4,9,9a-tetrahydro-7-[(2,4-difluorobenzyl)carbamoyl]-4-methyl-2H-1-oxa-4a,8a-diazaanthracene-6,10-dione
  • (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid-2,4 difluorobenzylamide
  • (4R,9aS)-N-(2,4-Difluorobenzyl)-5-hydroxy-3,4,6,9,9a,10-hexahydro-4-methyl-6,10-dioxo-2H-1-oxa-4a,8a-diazaanthracene-7-carboxamide
  • (4R,9aS)-N-(2,4-Difluorobenzyl)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diazaanthracene-7-carboxamide
  • 1051375-19-9
  • 1172581-47-3
  • 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)
  • 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir; GSK 1349572; S@fs:GSK1349572; Soltegravir; Tivicay; GSK 1349572B
  • 900515-16-4
  • DLU
  • Dolutegravi;GSK1349572;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;S/GSK1349572(GSK1349572);Dolutegravir;GSK1349572(dolutegravir);S/GSK1349572